I think it is clear that the "hot money" chasing the next big thing in HCV treatment has exited from Vertex stock. I believe this accounts for the rapid drop in share price from the 40's to the 20's around the time of the AASLD meeting. To say the selling was overdone I believe is an understatement. As the Vertex CFO, Ian Smith, said at the recent Piper Jaffray conference, he expects a fragmented market For HCV treatment in the latter half of this decade. Vertex's strategy is to capture pieces of this market and I expect they will succeed with this approach. No one can predict exactly how much of this market each of the companies will capture, but I bet no single company will dominate the HCV market the way Vertex does today. In addition to the parts of the HCV market that Vertex retains after 2014, there will be other significant revenue from non-HCV products coming out of the Vertex pipeline by 2014. The future is bright for Vertex and its stock price if you have the patience to hang on to your Vertex stock.